Allarity Therapeutics, Inc. (NasdaqCM: ALLR)
Health Care · Biotechnology · US
$0.90
-9.60% today · -40.7% 1Y
Allarity Therapeutics, Inc. (NasdaqCM: ALLR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.24M and employs 8 people.
Over the last twelve months the share price has lost 40.7%, trading between 0.77 and 1.84.
Tweenvest scores Allarity Therapeutics, Inc. across four factors: quality 37/100, value 67/100. Its strongest factor is value.
ALLR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.24M
- Revenue (TTM)
- $345.00K
- P/E
- —
- EPS
- -0.79
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- $1.84
- 52-week low
- $0.77
- Avg volume (3M)
- —
- Shares outstanding
- 15.91M
- Employees
- 8
- Next earnings
- —
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US0167445008
- Listed since
- Dec 21, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Initiator Pharma A/SOM: INIT | $14.45M | Skr2.09 | +16.11% |
| FunPep Company LimitedTSE: 4881 | $14.44M | ¥45.00 | +2.27% |
| NewcelX Ltd.NasdaqCM: NCEL | $14.44M | $2.50 | -17.90% |
| Aptamer Group PLCAIM: APTA | $14.29M | £0.00 | -4.62% |
| Abera Bioscience ABNGM: ABERA | $14.09M | Skr— | — |
| Pasithea Therapeutics Corp.NasdaqCM: KTTA | $14.03M | $0.42 | -10.16% |
| Xintela AB (publ)OM: XINT | $14.00M | Skr0.16 | -10.31% |
| BioCardia, Inc.NasdaqCM: BCDA | $13.93M | $0.92 | -11.53% |
Figures last refreshed Oct 18, 2026.